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ABSTRACT  
Aims: The aim of the present study was to immunohistochemically investigate the expression 
and prognostic significance of putative cancer stem cell markers CD117 (c-kit), CD34, CD20 
and CD15 in a cohort of patients with primary choroidal and ciliary body melanoma. 
Methods: The immunohistochemical expression of these markers was evaluated using DAB 
and AEC chromogens on paraffin-embedded tissue samples from 40 patients who underwent 
enucleation in the period from 1985 through 2000. Thirty-one patients had adequate tissue 
specimens for analysis.  
Results: CD117 overexpression was observed in 12 of the 31 samples (39%) when AEC 
chromogen was used and in 14 of 26 (54%) samples when DAB was used. CD15 positivity 
was seen in 3 out of 30 (10%) samples with AEC and in 6 out of 26 (23%) samples with 
DAB. CD20 and CD34 exhibited no positivity in the tested samples. During the follow-up 
time, 17 patients (55%) died due to metastatic disease. The Kaplan-Meier plots showed a 
significantly shorter overall and disease-free survival in CD117-positive patients when the 
AEC chromogen was used. CD15 expression had no impact on patients’ survival. In 
multivariate analysis, patients expressing the CD117 AEC had 4.13 times higher risk of lethal 
outcome in comparison with CD117 AEC negative patients.  
Conclusions: Our retrospective cohort study has for the first time demonstrated a small 
proportion of CD15-positive uveal melanomas. CD117 AEC overexpression was associated 
with a worse outcome in patients with choroidal and ciliary body melanoma. Further studies 
should confirm the validity of these observations and their potential for targeted treatment 
modalities. 
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INTRODUCTION 
Malignant melanoma arising in the uveal tract is a rare neoplasm constituting 
less than 1% of all malignant tumors, but represents the most common ocular 
malignancy in adults.[1, 2] 
Despite a good local control accomplished with radiotherapy, phototherapy, 
local resection or enucleation, a median survival reported in large studies was 7 
years.[3] Approximately half of the patients develop metastatic disease and die within 
15 years after diagnosis.[4] Metastases tend to be highly resistant to various treatment 
modalities.[3, 4] The risk of metastasis in choroidal and ciliary body melanomas is 
significantly higher than in melanomas of the iris, which justifies a separate 
investigation of these two uveal melanoma subgroups.[5]  
A slow progress in the treatment of the metastatic disease has renewed the interest in 
the cancer stem cell (CSC) model as a basis for the research of underlying molecular 
mechanisms.[6] Many putative cancer stem cell markers, including CD117, CD34, 
CD20 and CD15, have been proposed.[6-10] However, no universal cancer stem cell 
marker has been found to be expressed in all solid tumors.  
The transmembrane tyrosine kinase receptor CD117 (c-kit) is expressed in both 
normal and malignant tumors; the tumor expression includes both solid and 
hematological neoplasms. When activated by its ligand, known as stem cell factor 
(SCF), CD117 triggers signaling pathways that are involved in various cell functions 
including cell survival, proliferation, apoptosis, differentiation, and migration.[11] 
The percentage of primary uveal melanoma patients expressing the 
immunohistochemical marker CD117 has been reported to vary between 63% and 
87%,[12-15] while one study reported a 100% positivity rate.[16] No significant 
correlation between CD117 expression, with survival or metastasis formation, was 
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found in three studies that have investigated the prognostic significance of CD117 in 
patients with uveal melanoma.[12, 13, 16] 
The expression of other putative stem cell markers CD15, CD20, and CD34 on 
choroidal and/or ciliary body melanoma tissue samples has not yet been explored. In 
one melanoma cell line from the NCI60 tumor panel, 20.5% of tumor cells expressed 
CD15 when analyzed by flow cytometry.[10] CD15 is a cell surface carbohydrate 
antigen expressed on most differentiated myeloid cells, adult neural stem/progenitor 
cells, some epithelial cells, as well as in different cancers including lymphomas, 
carcinomas, and gliomas. The prognostic value of the expression of sialyated form of 
CD15 (sLe
x
) is still controversial, but positive correlation with poor outcome was 
shown in patients with colorectal cancer and breast cancer.[17] 
Glycoprotein CD34 is expressed by human myeloid and lymphoid progenitor 
cells, including the haemopoietic stem cells. It may also be expressed in vascular and 
spindle cell tumors and infrequently in cutaneous melanomas.[18] CD34 was one of 
the first specific markers found to be expressed in a subpopulation of cells capable of 
initiating tumors in an immunocompromised host.[7] Similarly, a minor subset of 
CD20-positive tumor cells that were isolated from cutaneous melanoma and detected 
by flow cytometry were recently shown to be capable of initiating new melanoma 
lesions when transplanted into immune-deficient NIH-III mice.[8]  Targeted 
elimination of CD20-positive melanoma cells resulted in complete and lasting 
eradication of established tumor lesions. 
The purpose of this study was to investigate the expression and prognostic 
significance of putative cancer stem cell markers CD117, CD34, CD20, and CD15 in a 
cohort of primary choroidal and ciliary body melanomas. 
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MATERIALS AND METHODS 
Patients 
Formalin-fixed paraffin-embedded tissue samples from 40 Caucasian patients 
with primary melanoma of the ciliary body or choroid, who have undergone 
enucleation in the period from 1985 through 2000, were retrieved from the archive at 
the Department of Pathology, University Hospital Center Zagreb. Only patients for 
whom data on the largest tumor diameter (LTD) was available, patients who did not 
receive irradiation or chemotherapy prior to enucleation, and those with minimum 
follow-up of 7 years, if alive, were included in the study.  
Nine patients were excluded from the study due to a) in 6 patients the tissue 
was not adequate for processing and staining due to suboptimal fixation or insufficient 
tumor tissue, b) two tumors were located in the iris, and c) extensive necrosis 
precluded appropriate evaluation in one patient. Final analysis included 31 patients. 
The study was approved by the Ethics Committee of Zagreb University Medical 
School. 
Methods 
Tissue samples were fixed in 10% buffered formalin and embedded in paraffin. 
Haematoxylin-eosin stained sections from each specimen were independently 
reviewed by two pathologists without knowledge of the clinical outcome (K.Z., S.D.). 
All tumors were classified according to the modified Callender classification.[19] 
Tumors composed only of spindle cells were classified as spindle cell melanomas, 
tumors containing both spindle and epithelioid cells as mixed, and tumors composed 
of more than 50% epithelioid cells as epithelioid melanomas.  
Immunohistochemical analysis was performed on deparaffinized tissue 
sections (4 µm), using following antibodies obtained from Dako (Glostrup, Denmark): 
mouse monoclonal CD15 (clone Carb-3, 1:30), CD20 (clone L26, 1:200), CD34 
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(clone QBEnd 10, 1:50) antibodies, and a rabbit polyclonal antibody CD117 (1:300). 
The staining was performed in Dako Autostainer Universal Staining System (Glostrup, 
Denmark) for all antibodies except CD15, which was stained manually. Antigen 
retrieval was performed with high-pH buffer 9.0 at 97ºC for 14 minutes. Following 
peroxidase block, visualization of the antigen–antibody complex was carried out with 
Dako EnVision FLEX system, using 3-amino-9-ethylcarbazole (AEC) and 3,3'-
diaminobenzidine tetrahydrochloride (DAB) as chromogens. Two chromogen 
protocols were used because of possible interference of the endogenous pigment with 
DAB-detection system in melanoma samples.[20, 21]  Also, in order to preserve the 
epitopes, no bleaching was applied. Consequently, 5 heavily pigmented melanomas 
stained with CD117 and DAB chromogen were excluded from further analysis. 
Finally, sections were counterstained with Mayer’s haematoxylin. Both positive and 
negative controls were included in all assays. 
The intensity of the staining and the percentage of positive tumor cells were 
evaluated by two blinded, independent pathologists (K.Z., S.D.). Samples were 
classified as positive if more than 10% of tumor cells displayed distinct 
immunostaining pattern, irrespective of the staining intensity. 
Statistics 
Overall (OS) and disease-specific (DS) survival were calculated as the time 
from diagnosis to the date of death (endpoint reached or censored) or last contact 
(censored) and plotted as survival curves according to the Kaplan–Meier method. The 
associations between CD117 expression and outcomes were analyzed using the log-
rank test. Univariate and multivariate analyses were performed using Cox 
proportional-hazards regression to analyze the effect of several parameters as possible 
independent risk factors on OS and DS. Cox regression statistics was presented with 
regression coefficient (b), standard error of regression coefficient (SE(b)), and hazard 
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ratio (HR) with 95% confidence intervals (95% CI). P-values lower than 0.05 were 
considered significant. Statistical analysis was done using IBM SPSS Statistics version 
21 (IBM, Armonk, NY, USA).   
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RESULTS 
Demographic and clinicopathologic characteristics of the cohort 
The results are outlined in Table 1. 
Among 31 patients with choroidal and ciliary body melanoma that fulfilled the 
entry criteria there were 16 women (52%) and 15 men (48%). The median age at the 
time of enucleation was 63 years (range 29-85 years). The average follow-up time was 
8.7 years (range 0.5-22 years). During the follow-up, 20 patients (65%) had died and 
17 patients (55%) of which were due to metastatic disease.  
Expression of immunohistochemical markers  
Immunohistochemical staining with CD117 showed immunoreactivity (>10% 
of the tumor cells) confined to the plasma membrane and/or cytoplasm in 12 of 31 
samples (39%) when AEC chromogen was used, and in 14 of 26 (54%) samples when 
DAB was used (Figure 1). Predominantly focal cytoplasmic positive reaction for 
CD15 was observed in 3 out of 30 (10%) samples with AEC chromogen and 6 out of 
26 (23%) samples with DAB (Table 1). Immunohistochemical staining for CD20 and 
CD34 with both chromogens revealed no positive tumor cells in any of the tested 
samples.  
Survival analysis 
The median OS for the studied patients was 8 years. The estimated five-year 
OS and DS was 67.7% (SE 8.4%) and 66.1% (SE 9.2%), respectively. The analysis of 
Kaplan-Meier plots showed a significantly shorter OS (p=0.005) and DS (p=0.009), as 
well as 5-year OS (Breslow, p=0.001) and DS (p=0.006) in CD117 positive patients 
when AEC chromogen was used (Figure 2). No significant difference was found when 
DAB was used as a chromogen for CD117 staining. CD15 expression had no influence 
on OS and DS when either chromogen was used. 
9 
 
Of 11 demographic and histopathologic parameters listed in Table 1, univariate 
analysis revealed significant associations between age (p=0.038), epithelioid tumor 
type (p=0-005), LTD>18 mm (p=0.016), positive CD117 AEC reaction (p=0.008) and 
OS, as well as between age (p=0.043), epithelioid type (p=0.013), positive CD117 
AEC reaction (p=0.014) and DS.  
In multivariate analysis CD117-positivity remained its significance for OS 
after adjusting for tumor type and age, as well as for DS after adjusting for tumor type, 
age, gender, lymphocyte infiltration and ciliary body involvement. Patients with 
CD117 positive melanomas analyzed with AEC chromogen had 4.13 times higher risk 
(p=0.017, 95% CI: 1.289-13.223) of lethal outcome in comparison with CD117 AEC 
negative cases. In the same model, age marginally influenced DS by increasing the 
hazard ratio for 4.3% every year (95% CI: 1.000-1.087, p=0.48; Table 2). 
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DISCUSSION 
The absence of lymphatic drainage in the non-inflamed uveal tract explains the 
lack of lymphatic spread in uveal melanoma. Hence, the only route of its invariably 
fatal metastatic spread is the hematogenous dissemination of tumor cells. The 
dichotomy of outcomes makes uveal melanoma a simple model for studying various 
potential prognostic factors in relatively small cohorts of patients.[22]  
The most intriguing characteristics of uveal melanoma cells are their extended 
period of proliferative quiescence and complete chemoresistance of disseminated 
tumor cells. A recent study has demonstrated a subpopulation of uveal melanoma cells 
that can sustain progression with increased resistance to chemotherapeutical agents 
[8]. It is postulated that these small subsets of cells can drive tumor initiation and 
progression resembling the resistance of normal stem cells to cytotoxic agents and 
radiation, hence the name cancer stem cells.[23]  
Many potential CSC markers have been described but so far no universal single 
immunohistochemical marker has been found. In this study we have investigated the 
expression and prognostic significance of routinely used antibodies against putative 
CSC markers CD15, CD20, CD34, and CD117 of which only CD15 and CD117 
exhibited positivity in the melanoma cells. The expression and prognostic value of 
CD117 has been well documented in various human cancers, often with variable and 
conflicting results.[24] PubMed literature search revealed only three studies that 
explored the expression and prognostic significance of CD117 in uveal melanoma.[12, 
13, 16] In these studies, as in our study, the OS and DS were shorter when compared 
with large epidemiological studies.[4] This result was expected because larger tumors 
are known to carry worse prognosis. In both our and the other three studies tumors 
were obtained by enucleation, which is mostly performed for tumors with larger LTD. 
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In the present study we have demonstrated a significant association between 
CD117 expression and OS and DS when the AEC chromogen was used. This finding 
is in contrast to the previously published data.[12, 13, 16] Since the obtained basic 
demographic data was comparably similar in all studies, the variability of fixation and 
immunohistochemical techniques might account for this discrepancy. It has been 
reported that variable antigen retrieval techniques, the dilutions and choice of 
antibodies or chromogens, as well as arbitrary cutoff values can influence the 
interpretation immunohistochemical analysis.[25] This variability might explain 
substantial differences in the proportion of CD117 positive tumors between the 
studies. The percentage of CD117 DAB positive patients in the study with the largest 
cohort of patients was 63%,[13] which is somewhat higher than in our study. In the 
same study, the percentage of CD117 positive samples was higher (88%) when 
Western blot technique on fresh frozen tumor samples was used, suggesting different 
detection thresholds for various methods. 
We have also shown a clear difference in the expression and prognostic 
significance of CD117 when different chromogens were used. As in the study by All 
Ericsson et al., we found no correlation with survival when DAB chromogen was 
used. We can hypothesize that this might be due to the higher specificity and lower 
sensitivity of AEC staining, especially since all AEC- positive samples in our study 
were also positive when DAB chromogen was used. The use of red chromogen is 
advised in melanoma because the endogenous brown pigment may interfere with the 
detection of the more commonly used DAB chromogen.[20, 21] We did not use 
bleaching to eliminate melanin from the DAB stains to avoid any additional alterations 
in the expression of antigens. The subsequent exclusion of highly pigmented samples 
in our DAB-stained series should not have significantly influenced the results due to 
the lack of prognostic significance of the pigmentation rate in our study. In the third 
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study by Luke et al., no prognostic value of high versus low CD117 expression was 
found. However, in the same study all uveal melanomas tested positive for CD117, 
making the analogy more difficult.   
Interestingly, Kaplan-Meier survival curves of CD117-positive and negative 
patients in the study from Mouriaux et al. who have also studied a subgroup of 
patients with choroidal and ciliary body melanoma using AEC as chromogen, were 
comparably similar to our CD117 AEC survival plots. In the same study the survival 
rate at 87 months was 35% for CD117 positive patients and 78% for CD117 negative 
patients, as compared to 33% and 78% in our study. The difference in the survival 
rates in that study did not reach statistical significance, but CD117 expression was 
positively associated with mitotic activity.  
To our knowledge, CD15 expression was not previously reported in patients 
with uveal melanoma. In our study, 10% to 23% of uveal melanoma samples 
displayed distinct and predominant focal positivity when AEC or DAB chromogen 
were used. Some authors suggest that the role of sLe
x
 in interactions between 
disseminated tumor cells and endothelial cells could provide a possible explanation for 
the correlation between sLe
x
 expression and poor outcome in patients with colorectal 
and breast cancer.[17] Our results did not demonstrate an association between CD15 
expression and survival, but the number of the CD15-positive uveal melanoma 
patients in our cohort was small. 
The prevention and treatment of metastatic uveal melanoma have not 
substantially improved in the last few decades.[15] A more personalized approach, 
which would include early stratification of patients according to verified prognostic 
factors and potential therapeutic response, is therefore required. Recent advances in 
molecular technologies, gene expression profiling in particular, have shown promising 
results in overcoming the weaknesses of traditional cytogenetic methods. These are 
13 
 
mostly attributed to the non-uniform distribution of cytogenetic abnormalities in uveal 
melanomas.[26]  
Nevertheless, immunohistochemistry is a widely available diagnostic tool for 
visualization of the antigen localization in the context of tissue morphology. In spite of 
CD117 overexpression in uveal melanoma and its possible prognostic significance, no 
significant clinical response to therapy with CD117 inhibitor imatinib mesylate was 
noted in CD117 positive patients.[11] Poor clinical efficacy may be attributed to the 
low frequency (1-10%) of KIT mutations in all types of ocular melanoma and a 
limited correlation between KIT mutations and CD117-positivity detected 
immunohistochemically.[14] Nevertheless, in patients with confirmed KIT mutations 
in skin melanomas, encouraging results of imatinib therapy were observed.[14] The 
more frequent mechanisms of CD117 overexpression might include SCF/CD117 
autocrine stimulation loop, gene amplification or constitutive phosphorylation of the 
receptor and dysfunction of phosphatases that turn off the activation.[13, 14]   
In summary, our study has for the first time revealed a small percentage of 
CD15-positive uveal melanomas. CD15 positivity was not associated with patients’ 
survival, which might be caused by a small sample size of our study. We have also 
demonstrated a correlation between CD117 expression and survival in patients with 
choroidal and ciliary body melanoma when AEC was used as the chromogen. Further 
studies should determine the validity of these markers in patient stratification and 
therapeutic considerations respecting the possible influence of the chosen technique on 
the final interpretation.  
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Key messages 
* A subset of choroidal and ciliary body melanomas overexpress the CD15 antigen. 
* CD117 overexpression can be associated with poor survival when AEC is used as a 
chromogen. 
* The use of different immunohistochemical techniques may significantly influence 
the final results. 
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Tables 
 
Table 1. Demographic and histopathologic characteristics of 31 patients with choroid 
and ciliary body melanoma 
 
 
 
                 * AEC - 3-amino-9-ethylcarbazole chromogen 
                 * DAB - 3,3'-diaminobenzidine tetrahydrochloride chromogen 
 
 
 
 
 
Patient characteristics Number (%) 
Age (years) Median  63 
Average (range) 59.2 (29-85) 
Age distribution (years) <60 13 (42%) 
>60 18 (58%) 
Gender Female 16 (52%) 
Male 15 (48%) 
 
Histologic type 
Spindle 7 (23%) 
Mixed 19 (61%) 
Epithelioid 5 (16%) 
 
Largest tumor diameter 
10-15 mm 14 (45%) 
15.1-18 mm  6 (19%) 
>18 mm 11 (36%) 
 
Pigment 
Low (<1/3 of the tumor) 9 (29%) 
Medium (<1/3 to 2/3 of the 
tumor) 
21 (68%) 
High (>2/3 of the tumor) 1 (3%) 
Ciliary body 
involvement 
Yes 4 (13%) 
No 27 (87%) 
Lymphocytic Infiltration Present 6 (19%) 
Not present 25 (81%) 
CD15 AEC Positive (>10%) 3 (10%) 
Negative 27 (90%) 
CD15 DAB Positive (>10%) 6 (23%) 
Negative 20 (77%) 
CD117 AEC* Positive (>10%) 12 (39%) 
Negative 19 (61%) 
CD117 DAB** Positive (>10%) 14 (54%) 
Negative 12 (46%) 
 
Survival 
Alive 11 (36%) 
Dead 20 (64%) 
Alive + Dead (other 
causes) 
14 (45%) 
Dead (uveal melanoma) 17 (55%) 
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Table 2  Prognostic impact of CD117 AEC expression, tumor cell type (spindle, mixed and 
epithelioid), age, gender, lymphocytic infiltration and ciliary body involvement on disease-
specific survival (Cox regression) 
 
Variable B SE HR p 95% CI 
 
CD117AEC 1,42 ,59 4,13 ,017 1,29 to 13,22 
Spindle    ,393  
Mixed 1,27 1,10 3,55 ,251 0,41 to 31,00 
Epithelioid 1,61 1,18 5,03 ,172 0,49 to 50,99 
Age ,04 ,02 1,04 ,048 1,00 to 1,09 
Gender -1,02 ,69 ,36 ,137 0,09 to 1,38 
Lymph inf* ,03 ,74 1,03 ,971 0,24 to 4,35 
CB inv.** ,04 ,91 1,04 ,967 0,17 to 6,22 
                  
* Lymph - lymphocytic infiltration;   
** CB inv. - ciliary body involvement 
 
B - regression coefficient, SE - standard error of regression coefficient, HR - hazard ratio,  95% CI - 
95% confidence intervals, p <0,05 indicates statistical significance 
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Figures 
 
 
 
Figure 1  A case of choroidal melanoma, mixed cell type, haematoxylin-eosin staining (a) 
(original magnification x 400). Tumor cells show strong and diffuse expression of CD117 
with DAB chromogen (b) (original magnification x 400) 
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Figure 2  Kaplan-Meier estimates for overall (a) and disease-specific survival (b) of 31 
patients with choroidal and ciliary body melanoma according to CD117 AEC positive (green 
line, N= 12) and CD117 negative (blue line, N=19) cases 
 
 
 
 
 
 
 
